ClinicalTrials.gov posted results on 15 September 2026 for a terminated trial evaluating neoadjuvant immunotherapy combinations in surgically resectable hepatocellular carcinoma. The study enrolled 62 participants; major pathologic response was 0% with atezolizumab plus bevacizumab and 3.3% with atezolizumab, bevacizumab, and tiragolumab.
Background
The study evaluated atezolizumab-based neoadjuvant immunotherapy combinations in participants with resectable hepatocellular carcinoma. The listed interventions were atezolizumab, bevacizumab, tiragolumab, and tobemstomig. The registry describes a platform design that could open new treatment arms, close arms showing minimal clinical activity or unacceptable toxicity, or modify the participant population.
Trial design
This Phase Ib/II, open-label, multicenter, randomized platform study was identified as NCT05908786 and enrolled 62 participants. Its overall status was terminated. The condition was hepatocellular carcinoma. The supplied record lists no primary-outcome entries. Reported measurements covered major pathologic response, pathologic complete response, relapse-free survival, event-free survival, overall survival, and overall survival rates at 6, 12, and 18 months.
Key results
Major pathologic response was 0% with atezolizumab plus bevacizumab and 3.3% with the three-drug combination. Pathologic complete response was 0% in both groups.
Median relapse-free survival was 11.86 months with atezolizumab plus bevacizumab and was reported as NA for the three-drug group. Median event-free survival was 14.46 months and 17.15 months, respectively. Median overall survival was reported as NA in both groups.
The overall survival rate at 6, 12, and 18 months was 93.33% with atezolizumab plus bevacizumab and 92.86% with atezolizumab, bevacizumab, and tiragolumab. The registry supplied no confidence-interval values, p-values, key analyses, or adverse-event summary for these measurements.
What this means
In this terminated study, the three-drug combination had a numerically higher major pathologic response rate than atezolizumab plus bevacizumab, while pathologic complete response was 0% in both groups. Event-free survival was reported for both groups, but the record provides no comparative analyses or confidence intervals. The absence of primary-outcome entries and the lack of supplied statistical analyses limit interpretation of differences between the treatment arms.
Source
Source: ClinicalTrials.gov, registry results for the terminated study “A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma,” posted 15 September 2026. Available at clinicaltrials.gov/study/NCT05908786.